<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00097240</url>
  </required_header>
  <id_info>
    <org_study_id>ACD3100g</org_study_id>
    <nct_id>NCT00097240</nct_id>
  </id_info>
  <brief_title>An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)</brief_title>
  <acronym>FOLLOW</acronym>
  <official_title>The Raptiva Pregnancy Registry: An Observational Study of the Use and Safety of Raptiva (Efalizumab) During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      The Raptiva Pregnancy Registry was a prospective observational study established to obtain
      data on pregnancy outcomes of women who were exposed to Raptiva.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">18</enrollment>
  <condition>Psoriasis</condition>
  <condition>Pregnancy</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women solicited through advertising, physician and patient awareness, and other
        programs.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Any patient who has used Raptiva within 6 weeks prior to conception or during her pregnancy
        may be included in the Registry. Enrollment is based on Raptiva exposure, whether
        inadvertent or deliberate, in relation to pregnancy. Enrollment should occur as early as
        possible during the pregnancy and must occur prior to knowledge of pregnancy outcome.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivor Caro, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FOLLOW Raptiva Pregnancy Registry</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>27560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2004</study_first_submitted>
  <study_first_submitted_qc>November 19, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2004</study_first_posted>
  <last_update_submitted>August 2, 2010</last_update_submitted>
  <last_update_submitted_qc>August 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Disclosures Group</name_title>
    <organization>Genentech, Inc.</organization>
  </responsible_party>
  <keyword>FOLLOW</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

